- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00373191
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at the effects of surgery, radiation therapy, chemotherapy, and hormone therapy on biomarkers in women with stage I, stage II, stage III breast cancer, or ductal carcinoma in situ that can be removed by surgery.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
- Measure the effects of surgery and radiation on concentrations of high-sensitivity C-reactive protein (hsCRP) in women with newly diagnosed stage I-III invasive breast cancer or ductal carcinoma in situ.
- Measure the effects of chemotherapy and/or endocrine therapy on concentrations of hsCRP in these patients.
- Summarize the differences in preoperative to peri-chemotherapy hsCRP concentrations separately for patients who do and who do not receive growth factors during chemotherapy.
- Observe the change in hsCRP concentrations and gene methylation over time with local and systemic treatment in these patients.
- Explore prevalence of baseline and change in methylation in a panel of genes that is known to be frequently and specifically hypermethylated in breast cancer.
OUTLINE: This is a prospective study.
A blood sample is collected at baseline, approximately 1 week after surgery, and at the time of a routine follow-up visit 3-6 months after completion of all local and systemic therapy, except for patients receiving endocrine therapy. For patients receiving adjuvant chemotherapy, a blood sample is collected prior to beginning chemotherapy and once during the final 2 courses of chemotherapy. For patients receiving radiotherapy, a blood sample is collected during the final 2 weeks of radiotherapy. For patients receiving endocrine therapy, a blood sample is collected between 2 and 6 months after starting endocrine therapy. Patients also complete a questionnaire about overall health and concurrent medications at baseline and during each follow-up visit.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
DISEASE CHARACTERISTICS:
Histologically and/or cytologically confirmed stage I-III invasive breast carcinoma or ductal carcinoma in situ
- Newly diagnosed disease
Patient must be initiating a new course of treatment for breast carcinoma, including surgery (mastectomy or lumpectomy with or without nodal evaluation) with or without any of the following:
- Radiation therapy
- Chemotherapy
- Endocrine therapy
- No known or suspected metastatic disease
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- No infectious or inflammatory condition, at the discretion of the principal investigator
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer
PRIOR CONCURRENT THERAPY:
More than 6 months since prior surgery
- Fine-needle aspirate or biopsy allowed
- More than 6 months since prior radiotherapy
- More than 6 months since prior chemotherapy
- More than 6 months since prior endocrine therapy
- No neoadjuvant endocrine therapy or chemotherapy
More than 2 weeks since prior and no concurrent regular use of any of the following:
- Hydroxymethyl glutaryl coenzyme A reductase inhibitor (statin)
- Nonsteroidal anti-inflammatory drug (NSAID)*
- Cyclooxygenase-2 (COX-2) inhibitor
- Aspirin*
- Acetaminophen and opioid use is permitted as needed NOTE: *Use of these products ≤ 2 times per week at standard over-the-counter doses allowed
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Change in high-sensitivity C-reactive protein and gene methylation over time
Tidsram: indefinite
|
indefinite
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- J0575 CDR0000485360
- P30CA006973 (U.S.S. NIH-anslag/kontrakt)
- JHOC-J0575 (Annan identifierare: SKCCC)
- JHOC-SKCCC-J0575 (Annan identifierare: SKCCC)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på chemotherapy
-
Hospital San Carlos, MadridAsociación de Afectados Por Tumores Cerebrales en España (ASATE)RekryteringGlioblastom | Glioblastoma Multiforme | Strålbehandling; Komplikationer | Glioblastom, IDH-vildtyp | Cancer hjärnaSpanien
-
Eli Lilly and CompanyAvslutadHER-2 positiv bröstcancer | Hormonreceptor positiv bröstcancerSpanien, Förenta staterna, Korea, Republiken av, Belgien, Frankrike, Tyskland, Italien, Australien, Argentina, Kanada, Storbritannien, Mexiko, Brasilien, Grekland
-
H. Lee Moffitt Cancer Center and Research InstituteServierRekryteringAkut lymfoblastisk leukemiFörenta staterna
-
Memorial Sloan Kettering Cancer CenterAktiv, inte rekryterandeKönscellscancerFörenta staterna